blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3353304

EP3353304 - VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE [Right-click to bookmark this link]
Former [2018/31]VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE AND/OR AMPHINASE
[2021/30]
StatusNo opposition filed within time limit
Status updated on  25.08.2023
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  16.09.2022
FormerGrant of patent is intended
Status updated on  10.04.2022
FormerExamination is in progress
Status updated on  10.07.2020
FormerRequest for examination was made
Status updated on  29.06.2018
FormerThe international publication has been made
Status updated on  01.04.2017
Most recent event   Tooltip07.06.2024Lapse of the patent in a contracting state
New state(s): MC		published on 10.07.2024  [2024/28]
Applicant(s)For all designated states
Okogen, Inc.
332 Encinitas Blvd., Suite 102
Encinitas, CA 92024 / US
[2018/31]
Inventor(s)01 / STREM, Brian
Okogen LLC
332 Encinitas Blvd., Suite 102
Encinitas, California 92024 / US
 [2018/31]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2018/31]
Application number, filing date16849832.725.09.2016
[2018/31]
WO2016US53629
Priority number, dateUS201562233267P25.09.2015         Original published format: US 201562233267 P
[2018/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017053923
Date:30.03.2017
Language:EN
[2017/13]
Type: A1 Application with search report 
No.:EP3353304
Date:01.08.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 30.03.2017 takes the place of the publication of the European patent application.
[2018/31]
Type: B1 Patent specification 
No.:EP3353304
Date:19.10.2022
Language:EN
[2022/42]
Search report(s)International search report - published on:US30.03.2017
(Supplementary) European search report - dispatched on:EP25.04.2019
ClassificationIPC:A61K38/46, C12N15/113, A61K9/00, A61P27/02
[2019/21]
CPC:
A61K38/465 (EP,IL,KR,US); A61K9/0048 (EP,IL,KR,US); A61K9/0051 (EP,IL,KR,US);
A61P27/02 (EP,IL,KR,US); C12N15/113 (IL,RU); C12Y301/27 (IL,KR,US);
C12Y301/27005 (EP,IL,US) (-)
Former IPC [2018/31]C12N15/113, A61K38/46
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/31]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:BEHANDLUNG VON VIRALER KONJUNKTIVITIS MIT RANPIRNASE[2021/30]
English:VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE[2021/30]
French:TRAITEMENT DE LA CONJONCTIVITE VIRALE À L'AIDE DE LA RANPIRNASE[2021/30]
Former [2018/31]BEHANDLUNG VON VIRALER KONJUNKTIVITIS MIT RANPIRNASE UND/ODER AMPHINASE
Former [2018/31]VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE AND/OR AMPHINASE
Former [2018/31]TRAITEMENT DE LA CONJONCTIVITE VIRALE À L'AIDE DE LA RANPIRNASE ET/OU DE L'AMPHINASE
Entry into regional phase23.04.2018National basic fee paid 
23.04.2018Search fee paid 
23.04.2018Designation fee(s) paid 
23.04.2018Examination fee paid 
Examination procedure23.04.2018Examination requested  [2018/31]
23.04.2018Date on which the examining division has become responsible
17.12.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
27.02.2020Amendment by applicant (claims and/or description)
14.07.2020Despatch of a communication from the examining division (Time limit: M06)
25.01.2021Reply to a communication from the examining division
16.09.2021Despatch of a communication from the examining division (Time limit: M02)
19.11.2021Reply to a communication from the examining division
11.04.2022Communication of intention to grant the patent
18.08.2022Fee for grant paid
18.08.2022Fee for publishing/printing paid
18.08.2022Receipt of the translation of the claim(s)
Opposition(s)20.07.2023No opposition filed within time limit [2023/39]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
27.02.2020Request for further processing filed
27.02.2020Full payment received (date of receipt of payment)
Request granted
10.03.2020Decision despatched
Fees paidRenewal fee
15.10.2018Renewal fee patent year 03
03.09.2019Renewal fee patent year 04
08.09.2020Renewal fee patent year 05
09.09.2021Renewal fee patent year 06
08.09.2022Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
30.09.201803   M06   Fee paid on   15.10.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL19.10.2022
AT19.10.2022
CZ19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
IT19.10.2022
LT19.10.2022
LV19.10.2022
MC19.10.2022
NL19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SI19.10.2022
SK19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
[2024/28]
Former [2024/26]AL19.10.2022
AT19.10.2022
CZ19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
IT19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SI19.10.2022
SK19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/51]AL19.10.2022
AT19.10.2022
CZ19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SI19.10.2022
SK19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/38]AL19.10.2022
AT19.10.2022
CZ19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SK19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/37]AL19.10.2022
AT19.10.2022
CZ19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/35]AT19.10.2022
CZ19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/34]AT19.10.2022
DK19.10.2022
EE19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/33]AT19.10.2022
DK19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/26]AT19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
PL19.10.2022
RS19.10.2022
SE19.10.2022
NO19.01.2023
GR20.01.2023
IS19.02.2023
PT20.02.2023
Former [2023/24]AT19.10.2022
ES19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
SE19.10.2022
NO19.01.2023
GR20.01.2023
PT20.02.2023
Former [2023/23]AT19.10.2022
ES19.10.2022
FI19.10.2022
LT19.10.2022
LV19.10.2022
NL19.10.2022
SE19.10.2022
NO19.01.2023
GR20.01.2023
PT20.02.2023
Former [2023/22]AT19.10.2022
ES19.10.2022
FI19.10.2022
LT19.10.2022
NL19.10.2022
SE19.10.2022
NO19.01.2023
PT20.02.2023
Former [2023/20]LT19.10.2022
NL19.10.2022
NO19.01.2023
Former [2023/17]NL19.10.2022
Documents cited:Search[AP]WO2015148768  (TAMIR BIOTECHNOLOGY INC [US]) [AP] 1-15* the whole document *;
 [E]WO2016205109  (TAMIR BIOTECHNOLOGY INC [US]) [E] 1-9 * the whole document *;
 [AD]  - ERIC G. ROMANOWSKI ET AL, "The In Vitro and In Vivo Evaluation of ddC as a Topical Antiviral for Ocular Adenovirus Infections", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, US, (20091101), vol. 50, no. 11, doi:10.1167/iovs.08-3286, ISSN 1552-5783, pages 5295 - 5299, XP055581166 [AD] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1167/iovs.08-3286
International search[Y]US2009047665  (HALL THOMAS A [US], et al);
 [Y]US8518399  (SAXENA SHAILENDRA K [US], et al);
 [Y]WO2015110429  (NICOX SA [FR]);
ExaminationUS2016361392
by applicantUS5559212
 US5728805
 US6175003
 US6239257
 US6423515
 US7229824
 US7442535
 US7442536
 US7473542
 US7556953
 US7556951
 US7556952
 US7585655
 US7585654
 US7763449
 US8518399
 US8663964
 US8808690
 WO2016205109
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.